618061-76-0

Basic information

• Product Name: (S)-diethyl 2-(4-(3-chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-ylamino)-2-oxoethylphosphonate
• Synonyms: Diethyl {[4-(3-Chloro-4-Fluoro-PhenylaMino)-7-((S)-Tetrahydrofuran-3-Yloxy)-Quinazolin-6-YlcarbaMoyl]-Methyl}-Phosphonate;Phosphonic acid, P-[2-[[4-[(3-chloro-4-fluorophenyl)aMino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]aMino]-2-oxoethyl]-, diethyl ester;P-[2-[[4-[(3-Chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]amino]-2-oxoethyl]phosphonic acid diethyl ester (S)-diethyl 2-(4-(3-chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-ylamino)-2-oxoethy;diethyl (S)-(2-((4-((3-chloro-4-fluorophenyl)amino)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)amino)-2-oxoethyl)phosphonate;(S)-Diethyl 2-(4-(3-chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-ylamin;(S)-diethyl 2-(4-(3-chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-ylamino)-2-oxoethylphosphonate;P-[2-[[4-[(3-Chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]amino]-2-oxoethyl]phosphonic acid diethyl ester;N-[4-(3-chloro-4-fluo
• CAS NO: 618061-76-0
• Molecular Formula: C₂₄H₂₇ClFN₄O₆P
• Molecular Weight: 553
• EINECS: -0
• Mol File: 618061-76-0.mol

Chemical Properties

• Boiling Point: 709.948 °C at 760 mmHg
• Flash Point: 383.163 °C
• Appearance: /
• Density: 1.425
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• CAS DataBase Reference: (S)-diethyl 2-(4-(3-chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-ylamino)-2-oxoethylphosphonate(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-diethyl 2-(4-(3-chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-ylamino)-2-oxoethylphosphonate(618061-76-0)
• EPA Substance Registry System: (S)-diethyl 2-(4-(3-chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-ylamino)-2-oxoethylphosphonate(618061-76-0)

Safety Data

• Hazardous Substances Data: 618061-76-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(S)-diethyl 2-(4-(3-chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-ylamino)-2-oxoethylphosphonate is used as an impurity in the synthesis and production of Afatinib. It plays a crucial role in the development and manufacturing process of this anticancer drug, ensuring the purity and efficacy of the final product.
Used in Cancer Treatment:
As an impurity of Afatinib, (S)-diethyl 2-(4-(3-chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-ylamino)-2-oxoethylphosphonate contributes to the overall therapeutic effect of the drug. Afatinib is used for treating various types of cancer, including those affecting the respiratory tract, lungs, gastrointestinal tract, bile duct, and gallbladder. (S)-diethyl 2-(4-(3-chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-ylamino)-2-oxoethylphosphonate's unique structure allows it to target specific cellular pathways and inhibit the growth and proliferation of cancer cells.
Used in Research and Development:
(S)-diethyl 2-(4-(3-chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-ylamino)-2-oxoethylphosphonate is also used in research and development for the discovery of new drugs and therapies. Its unique chemical properties and interactions with biological systems make it a valuable tool for studying the mechanisms of action and potential applications of quinazoline derivatives in medicine.

Upstream product

• 314771-76-1 N₄-(3-chloro-4-fluorophenyl)-7-((tetrahydrofuran-3-yl)oxy) quinazoline-4,6-diamine 
• 314771-76-1 6-Amino-4-[(3-chloro-4-fluorophenyl)amino]-7-[(S)-(tetrahydrofuran-3-yl)oxy]quinazoline 
• 3095-95-2 diethylphosphonoacetic acid 
• 762-04-9 phosphonic acid diethyl ester 
• 530-62-1 1,1'-carbonyldiimidazole 
• 162012-67-1 N-(3-chloro-4-fluorophenyl)-7-fluoro-6-nitroquinazolin-4-amine 
• 314771-88-5 4-[(3-chloro-4-fluorophenyl)amino]-6-nitro-7-[(S)-(tetrahydrofuran-3-yl)oxy]quinazoline 

Downstream Products

• 749879-39-8 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(homomorpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-[(S)-(tetrahydrofuran-3-yl)oxy]quinazoline 
• 850140-72-6 afatinib 
• 850140-73-7 2-butenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-([(3S)-tetrahydro-3-furanyl]oxy)-6-quinazolinyl)-4-(dimethylamino)-, (2E)-, (2Z)-2-butenedioate 
• 1398313-22-8 afatinib citrate 
• 1398312-22-5 afatinib fumarate 
• 1680184-59-1 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-((R)-tetrahydrofuran-3-yloxy)-quinazoline 
• 850140-73-7 (S,E)-N-(4-(3-chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide dimaletate 
• 1680184-59-1 (Z)-4-dimethylamino-but-2-enoic acid-[4-(3-chloro-4-fluoro-phenylamino)-7-((S)-tetrahydrofuran-3-yloxy)-quinazolin-6-yl]amide 
• 1680184-59-1 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-[(S)-(tetrahydrothran-3-yl)oxy]quinazoline 

Relevant articles and documents

Compound, and preparation method and application thereof

The invention relates to a compound, and a preparation method and application thereof. Specifically, the compound is as shown in a formula 1 which is described in the specification. The invention also provides the preparation method for the compound as shown in the formula 1. The preparation method comprises a step of contacting N-[4-[(3-chloro-4-fluorophenyl)amino]-7[[(3S)-tetrahydro-3-furyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-2-butyleneamide with an alkaline aqueous solution in an organic solvent so as to obtain the compound as shown in the formula 1. The preparation method is simple to operate; a white powder product can be obtained through direct filtering after post-treatment; and the prepared compound has high purity, as high as 99% or above, and can be directly used as an impurity control substance for research on the quality of an afatinib bulk drug.

CRYSTALLINE FORMS OF AFATINIB DI-MALEATE

The present disclosure encompasses crystalline forms of Afatininb di-maleate and methods of their use.

PROCESS FOR PREPARING AMINOCROTONYLAMINO-SUBSTITUTED QUINAZOLINE DERIVATIVES

The invention relates to an improved process for preparing aminocrotonylamino-substituted quinazoline derivatives of general formula (I) wherein the groups Ra, Rb, Rc and Rd have the meanings given in the claims, as well as sulphonyl derivatives of formula (XIII) and the use thereof as synthesis components for preparing quinazolines of formula (I). The quinazoline derivatives of formula (I) are inhibitors of signal transduction mediated by tyrosinekinases and by the Epidermal Growth Factor-Receptor (EGF-R) and are therefore particularly suitable for the treatment of tumoral diseases.

Process for preparing amino crotonyl compounds

The invention relates to an improved process for preparing 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylam ino)-1 -oxo-2-buten-1 -yl]am ino}-7-((S)-tetrahydrofuran-3-yloxy)-quinazoline and related aminocrotonyl compounds and the preparation of a suitable salt of 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1 -oxo-2-buten-1 -yl]amino}-7-((S)-tetrahydrofuran-3-yloxy)-quinazoline for use as a pharmaceutically active substance.

Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them

The present invention relates to bicyclic heterocycles of general formula wherein Ra, Rb, Rc, Rd, Re and X are defined as in claim 1, the tautomers, the stereoisomers, the mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids, which have valuable pharmacological properties, particularly an inhibitory effect on signal transduction mediated by tyrosine kinases, the use thereof for treating diseases, particularly tumoral diseases and benign prostatic hyperplasia (BPH), diseases of the lungs and respiratory tract, and the preparation thereof.

BICYCLIC HETEROCYCLES, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF, AND METHOD FOR THE PRODUCTION THEREOF

The invention relates to bicyclic heterocycles of general formula (I), wherein Ra, Rb, Rc, Rd, Re, and X have the definitions indicated in claim 1, the tautomers, stereoisomers, mixtures, and salts thereof, especially the physiologically acceptable salts thereof containing inorganic or organic acids having valuable pharmaceutical properties, especially an inhibiting effect on signal transduction mediated by tyrosine kinases, the use thereof for treating diseases, especially cancer diseases and benign prostatic hyperplasia (BPH), diseases of the lungs and respiratory tract, and the production thereof.